SMT Engineering Limited shareholders approved all 11 resolutions tabled at the Annual General Meeting held on September 30, 2026. The meeting, conducted via video conferencing, saw a voting turnout of 79.33% of outstanding shares.

Key approvals included the adoption of standalone and consolidated financial statements for FY26 and the re-appointment of director Vishal Jaiswal. Shareholders also authorized an increase in authorised share capital from ₹18.10 crore to ₹19.10 crore to accommodate potential equity expansion.

Capital Structure and Related Party Approvals

The company sought and received approval to increase its authorised share capital. This move expands the capital base from ₹18.10 crore (1,81,00,000 shares) to ₹19.10 crore (1,91,00,000 shares) of ₹10 face value each. Additionally, shareholders approved the issue of up to 1,42,858 convertible share warrants to identified promoters on a preferential basis, convertible within 18 months.

A significant portion of the agenda focused on ratifying material related party transactions. These included dealings between material subsidiary Sai Machine Tools Private Limited and entities such as Prakash Industries, SMT Plast, and Softcare Solutions. Transactions involving Chemerix Life Sciences Private Limited and Mr. Ajay Jaiswal were also ratified.

Voting Pattern and Promoter Interest

Voting results reveal a distinct pattern regarding promoter participation. For resolutions where promoters were deemed interested parties (Resolutions 3, 5, and 6 through 11), their votes were treated as invalid under SEBI regulations. Consequently, these resolutions relied entirely on public shareholder votes for passage.

For non-interested resolutions like the financial statement adoption and capital increase, promoter votes contributed significantly to the majority, with 12,186,724 votes cast in favour out of 14,334,445 total votes polled.

What the Numbers Show

The voting data highlights a high concentration of power in the hands of the promoter group, who hold 12,186,724 shares against 5,883,276 held by public non-institutions. However, for six of the eleven resolutions, this dominance was neutralized by regulatory requirements excluding interested party votes. In these cases, the public minority effectively decided the outcome, with 99.99% of valid public votes supporting management proposals. This suggests strong alignment between the promoter's strategic direction and the sentiment of the participating retail investor base, despite the low institutional presence.

SMT Engineering issued a corrigendum to its Annual General Meeting (AGM) notice on September 21, 2026, addressing inadvertent errors in Item 5 concerning a proposed preferential issue. The company scheduled the AGM for September 30, 2026, to be conducted via video conferencing or other audio-visual means.

The correction modifies the explanatory statement related to the preferential allotment. Specifically, the company clarified the total number of warrants associated with the issue. The revised figure states the total number of warrants as 1,42,858.

Utilization of Proceeds

The corrigendum also updates the description of how the funds from the preferential issue will be deployed. The company stated that the proposed funds will be utilized for investment in Chemerix Life Sciences Private Limited, a step-down wholly owned subsidiary. The capital expenditure aims to set up a manufacturing unit, with additional proceeds allocated for general corporate purposes.

The detailed breakdown of the estimated amount to be utilized is as follows:

The general corporate purposes component, capped at ₹10,00,000, will address ongoing exigencies, contingencies, and expenses as decided by the Board. The company noted that these figures consider 100% conversion of warrants into equity shares within the stipulated time.

What the Numbers Show

The preferential issue structure indicates a heavy concentration of capital deployment toward a specific strategic vertical. With ₹3,90,00,240 allocated to Chemerix Life Sciences against a total raise of ₹4,00,00,240, approximately 97.5% of the proceeds are earmarked for this single subsidiary’s manufacturing setup. This suggests the company is leveraging equity financing primarily to fund expansion in the life sciences segment rather than for broad-based working capital needs.